Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension

Abstract excerpt

Right ventricular failure (RVF) is the most frequent cause of death in patients with pulmonary arterial hypertension (PAH); however, specific therapies targeted to treat RVF have not been developed. Chronic treatment with carvedilol has been shown to reduce established maladaptive right ventricle (RV) hypertrophy and to improve RV function in experimental PAH. However, the mechanisms by which carvedilol improves...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiac Fibrosis and Remodeling
• Share to MicroRNA in disease regulation
• Share to Pulmonary Hypertension Research and Treatments